Prelude Therapeutics Inc
PRLD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PRLD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRLD
Prelude Therapeutics Inc is a clinical-stage oncology company developing targeted therapies, including a CALR/SMARCA2/4 degrader antibody conjugate, with no approved products and a history of operating losses.
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 6 clinical trials for Prelude Therapeutics Inc.
Prelude Therapeutics Inc is a clinical-stage oncology company developing targeted therapies, including a CALR/SMARCA2/4 degrader antibody conjugate, with no approved products and a history of operating losses.
- Prelude is a clinical-stage, fully integrated oncology company focused on developing drug candidates targeting cancer drivers [sec_mda · as of 2025-03-10].
- The company's preclinical data show a CALR/SMARCA2/4 degrader antibody conjugate can selectively degrade SMARCA2/4 in CALR mutant cells and inhibit growth in vitro and in vivo [sec_mda · as of 2026-08-11].
- As of June 30, 2026, Prelude reported cash & equivalents of $29.7M, total revenue of $5.7M, and a net loss of $13.9M for the six-month period [sec].
- The company has an accumulated deficit of $683.1M as of December 31, 2025, and expects to continue incurring significant expenses and operating losses for the foreseeable future [sec_mda · as of 2026-03-10].
- Prelude has no credit facility or committed sources of capital and will need additional funds to meet operational needs and capital requirements for clinical trials and other activities [sec_mda · as of 2026-08-11].
What works
- Prelude is a clinical-stage oncology company with a foundation in drug discovery, indicating a pipeline of internally developed candidates [sec_mda · as of 2025-03-10].
- Preclinical data demonstrate a CALR/SMARCA2/4 degrader antibody conjugate can selectively target and inhibit CALR-mutant cell growth, suggesting a novel therapeutic approach [sec_mda · as of 2026-08-11].
- The company has a shelf registration statement filed in May 2024, providing a potential mechanism to raise capital through the issuance of securities [sec_mda · as of 2026-08-11].
What to weigh
- Prelude has incurred recurring losses and negative cash flows from operations, with a net loss of $24.3 million for the six months ended June 30, 2026 [sec_mda · as of 2026-08-11].
- The company has no approved products and does not expect to generate product revenue for several years, if at all [sec_mda · as of 2026-03-10].
- Prelude has no credit facility or committed sources of capital, and its future funding requirements are uncertain due to numerous risks in drug development [sec_mda · as of 2026-08-11].
- As of December 31, 2025, the company had an accumulated deficit of $683.1 million, reflecting substantial historical losses [sec_mda · as of 2026-03-10].
From the filings
Quoted directly from source documents.
Prelude is a clinical-stage oncology company.
“Prelude is a clinical-stage fully integrated oncology company built on a foundation of dr”
SEC MD&A · March 10, 2025
Preclinical data show a CALR/SMARCA2/4 degrader antibody conjugate can selectively degrade SMARCA2/4 in CALR mutant cells and inhibit growth.
“data demonstrate that a CALRxSMARCA2/4 degrader antibody conjugate can selectively degrade SMARCA2/4 in CALR mutant cells and robustly inhibit CALR-mutant cell growth in vitro and in vivo.”
SEC MD&A · August 11, 2026
Prelude has incurred recurring losses and negative cash flows.
“We have incurred recurring losses, the majority of which are attributable to research and development activities, and negative cash flows from operations.”
SEC MD&A · August 11, 2026
Prelude has no credit facility or committed sources of capital.
“We currently have no credit facility or committed sources of capital.”
SEC MD&A · August 11, 2026
Risks & what to watch (4)›
Key risks
- No approved products — Prelude has no approved products and does not expect to generate product revenue for several years, if at all [sec_mda · as of 2026-03-10].
- Significant accumulated deficit — As of December 31, 2025, accumulated deficit was $683.1 million, reflecting substantial historical losses [sec_mda · as of 2026-03-10].
- Uncertain funding requirements — The company is unable to estimate exact operating capital requirements due to numerous risks in drug development [sec_mda · as of 2026-08-11].
- No committed capital sources — Prelude has no credit facility or committed sources of capital, relying on equity sales for funding [sec_mda · as of 2026-08-11].
What to watch
- Progress of clinical trials for product candidates, as the company is clinical-stage and development outcomes are key [sec_mda · as of 2025-03-10].
- Future capital raises or partnerships, given the need for additional funds and no committed capital sources [sec_mda · as of 2026-08-11].
- Updates on the CALR/SMARCA2/4 degrader antibody conjugate program, which has shown promising preclinical data [sec_mda · as of 2026-08-11].
- Changes in cash position and operating expenses, as the company continues to incur losses and negative cash flows [sec_mda · as of 2026-08-11].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Prelude Therapeutics Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Prelude Therapeutics Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
28.7 months
D/E 0.42 · 0% dilution
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
6 buys · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
53
Total value held
$98.9M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 10,909,256 | $37.3M |
| baker bros. advisors lp | 10,123,824 | $34.6M |
| vanguard capital management llc | 2,460,812 | $8.4M |
| two sigma investments, lp | 923,626 | $3.2M |
| sphera funds management ltd. | 558,339 | $1.9M |
| millennium management llc | 382,737 | $1.3M |
| marshall wace, llp | 358,906 | $1.2M |
| morgan stanley | 322,161 | $1.1M |
| blackrock, inc. | 321,886 | $1.1M |
| geode capital management, llc | 302,458 | $1.0M |
Showing top 10 of 53 institutional holders of Prelude Therapeutics Inc. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 15.1%
- Days to cover
- 7.2
- Shares short
- 1,807,780
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRLD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Prelude Therapeutics Inc?
Prelude Therapeutics Inc is a clinical-stage oncology company developing targeted therapies, including a CALR/SMARCA2/4 degrader antibody conjugate, with no approved products and a history of operating losses.
What is Prelude Therapeutics Inc's lead drug candidate?
Prelude Therapeutics Inc's most advanced tracked candidate is kat6a degrader (Preclinical) for ER+ breast cancer.
Who is the CEO of Prelude Therapeutics Inc?
Dr. Krishna Vaddi D.V.M., Ph.D. is the chief executive officer of Prelude Therapeutics Inc (PRLD).
Where is Prelude Therapeutics Inc headquartered?
Prelude Therapeutics Inc (PRLD) is headquartered in Wilmington, DE, United States.
What therapeutic areas does Prelude Therapeutics Inc focus on?
Prelude Therapeutics Inc develops therapies across Oncology, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.